Intravenous Interferon During Liver Transplant

N/ACompletedNCT01192698

Wake Forest University Health Sciences15 enrolled

Overview

The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation. The hypothesis is that patients who receive ribavirin immediately before transplant and intravenous interferon alfa 2b during the anhepatic phase(while the liver is removed)will have sustained virologic response post liver transplant.

The study is evaluating intravenous interferon given during the anhepatic phase of lvier transplant. Ribavirin was given as well. Serial measurements for HCV RNA were determined 12, 24 72, 96 hrs and 4 weeks after liver transplant.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hepatitis C Cirrhosis

Interventions

IV interferonDRUG

IV interferon 5MU during anhepatic phase

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * liver transplant for hepatitis c Exclusion Criteria: * allergy to interferon

Outcomes

Primary Outcomes

HCV RNA Result

Will measure mean HCV RNA levels 4 weeks after liver transplant

Time frame: 4 weeks after liver transplant

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.